PL3432899T3 - Zastosowanie probiotyków w leczeniu i/lub zapobieganiu łuszczycy - Google Patents

Zastosowanie probiotyków w leczeniu i/lub zapobieganiu łuszczycy

Info

Publication number
PL3432899T3
PL3432899T3 PL17722689T PL17722689T PL3432899T3 PL 3432899 T3 PL3432899 T3 PL 3432899T3 PL 17722689 T PL17722689 T PL 17722689T PL 17722689 T PL17722689 T PL 17722689T PL 3432899 T3 PL3432899 T3 PL 3432899T3
Authority
PL
Poland
Prior art keywords
probiotics
psoriasis
prevention
treatment
Prior art date
Application number
PL17722689T
Other languages
English (en)
Inventor
Vicente Manuel Navarro López
Ana Adela RAMÍREZ BOSCÁ
José Manuel Pérez Orquín
Daniel RAMÓN VIDAL
Salvador GENOVÉS MARTÍNEZ
María Empar Chenoll Cuadros
Francisco Manuel Codoñer Cortés
Original Assignee
Bionou Research, S.L.
Biopolis, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionou Research, S.L., Biopolis, S.L. filed Critical Bionou Research, S.L.
Publication of PL3432899T3 publication Critical patent/PL3432899T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL17722689T 2016-03-21 2017-03-21 Zastosowanie probiotyków w leczeniu i/lub zapobieganiu łuszczycy PL3432899T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382122.6A EP3222282A1 (en) 2016-03-21 2016-03-21 Use of probiotics in the treatment and/or prevention of psoriasis
PCT/EP2017/056719 WO2017162683A1 (en) 2016-03-21 2017-03-21 Use of probiotics in the treatment and/or prevention of psoriasis
EP17722689.1A EP3432899B1 (en) 2016-03-21 2017-03-21 Use of probiotics in the treatment and/or prevention of psoriasis

Publications (1)

Publication Number Publication Date
PL3432899T3 true PL3432899T3 (pl) 2021-11-22

Family

ID=55969084

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17722689T PL3432899T3 (pl) 2016-03-21 2017-03-21 Zastosowanie probiotyków w leczeniu i/lub zapobieganiu łuszczycy

Country Status (24)

Country Link
US (1) US10912802B2 (pl)
EP (2) EP3222282A1 (pl)
KR (1) KR102303587B1 (pl)
CN (1) CN110325198B (pl)
AR (1) AR107921A1 (pl)
AU (1) AU2017238300B2 (pl)
DK (1) DK3432899T3 (pl)
EA (1) EA201891908A1 (pl)
ES (1) ES2873889T3 (pl)
HR (1) HRP20211173T1 (pl)
HU (1) HUE055635T2 (pl)
IL (1) IL261932B2 (pl)
MA (1) MA43488B1 (pl)
MX (1) MX389112B (pl)
MY (1) MY193275A (pl)
PE (1) PE20190432A1 (pl)
PH (1) PH12018502042B1 (pl)
PL (1) PL3432899T3 (pl)
PT (1) PT3432899T (pl)
RS (1) RS62101B1 (pl)
RU (1) RU2767967C2 (pl)
SI (1) SI3432899T1 (pl)
UA (1) UA127180C2 (pl)
WO (1) WO2017162683A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800002052A1 (it) * 2018-01-26 2019-07-26 Girolamo Stefano Di Probiotico per il trattamento della psoriasi
EP3851115A1 (en) * 2020-01-15 2021-07-21 Biopolis, S.L. Probiotic composition for its use as an antioxidant
US20210275612A1 (en) * 2020-03-09 2021-09-09 Glac Biotech Co., Ltd. Method for alleviating inflammation-related disorder
CN113142554A (zh) * 2020-06-09 2021-07-23 江苏佰澳达生物科技有限公司 一种改善头皮屑产生的益生菌发酵液及其应用
EP3967318A1 (en) 2020-09-14 2022-03-16 Bionou Research, S.L. Probiotic compositions for the treatment of acne
CN112159778B (zh) * 2020-09-30 2021-12-03 江南大学 一株可缓解银屑病的动物双歧杆菌及其应用
WO2022090474A1 (en) * 2020-10-29 2022-05-05 Deerland Probiotics & Enzymes A/S Microencapsulated microbial composition
CN112546074B (zh) * 2020-12-24 2022-09-27 江南大学 一株能够抑制IL-23、Th17轴相关炎症因子释放的短双歧杆菌及其应用
CN112812989B (zh) * 2020-12-31 2022-06-10 江南大学 一种能够缓解银屑病的青春双歧杆菌及其应用
EP4294416A1 (en) * 2021-02-17 2023-12-27 Axisbiotix Limited Composition and use thereof
CN113088473B (zh) * 2021-04-27 2022-08-02 江南大学 一株具有缓解HaCaT细胞氧化损伤作用的动物双歧杆菌
CN113455549B (zh) * 2021-06-29 2022-09-13 黑龙江飞鹤乳业有限公司 一种奶酪产品及其制备方法和应用
KR20240130711A (ko) * 2021-12-16 2024-08-29 바이오폴리스, 에스.엘. 불안 장애의 치료 및/또는 예방에 있어서 포스트바이오틱스의 용도
KR102854932B1 (ko) * 2023-07-03 2025-09-05 코스맥스 주식회사 비피도박테리움 애니멀리스 서브스페시스 락티스 균주 및 그의 모발 또는 두피 상태 개선 용도
CN118421507A (zh) * 2024-04-22 2024-08-02 广东行海生物科技有限公司 一种医用细胞CMU-Pb-12联合地塞米松在制备防治银屑病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070260A1 (en) * 2002-02-21 2003-08-28 Societe Des Produits Nestle S.A. A photoprotective orally administrable composition for skin
JP2004250337A (ja) 2003-02-18 2004-09-09 Sunstar Inc アレルギー疾患改善用製剤
ZA200802934B (en) * 2005-10-06 2009-09-30 Probi Ab Use of lactobacillus for treatment of virus infections
AU2006297896B2 (en) * 2005-10-06 2011-12-08 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
PL2704704T3 (pl) * 2011-05-03 2019-04-30 Dupont Nutrition Biosci Aps Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
KR20130049554A (ko) 2011-11-04 2013-05-14 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물
KR101453982B1 (ko) * 2012-09-19 2014-10-28 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101724601B1 (ko) 2014-11-04 2017-04-10 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물
ES2575828B1 (es) * 2014-12-31 2017-07-07 Universidad De León Empleo de probióticos en el incremento de la fertilidad masculina
TWI829098B (zh) * 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物

Also Published As

Publication number Publication date
HUE055635T2 (hu) 2021-12-28
RU2018136939A (ru) 2020-04-22
ES2873889T3 (es) 2021-11-04
AU2017238300A1 (en) 2018-11-01
US10912802B2 (en) 2021-02-09
UA127180C2 (uk) 2023-05-31
AR107921A1 (es) 2018-06-28
IL261932A (en) 2018-10-31
IL261932B2 (en) 2023-04-01
CA3018625A1 (en) 2017-09-28
DK3432899T3 (da) 2021-07-05
MX389112B (es) 2025-03-20
KR102303587B1 (ko) 2021-09-17
SI3432899T1 (sl) 2021-12-31
PH12018502042A1 (en) 2019-07-15
EP3432899A1 (en) 2019-01-30
MA43488B1 (fr) 2020-10-28
RU2018136939A3 (pl) 2020-05-13
PT3432899T (pt) 2021-07-05
MY193275A (en) 2022-09-29
RS62101B1 (sr) 2021-08-31
MA43488A1 (fr) 2019-12-31
KR20190008849A (ko) 2019-01-25
WO2017162683A1 (en) 2017-09-28
EP3222282A1 (en) 2017-09-27
BR112018069284A2 (pt) 2019-03-06
AU2017238300B2 (en) 2024-07-11
PH12018502042B1 (en) 2024-02-21
EA201891908A1 (ru) 2019-04-30
IL261932B (en) 2022-12-01
MX2018011593A (es) 2020-01-30
HRP20211173T1 (hr) 2021-10-15
CN110325198A (zh) 2019-10-11
CN110325198B (zh) 2024-04-30
NZ747129A (en) 2025-02-28
EP3432899B1 (en) 2021-04-28
US20190328799A1 (en) 2019-10-31
PE20190432A1 (es) 2019-03-21
RU2767967C2 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
IL259751B (en) Polycyclic compounds and their use in the treatment of immune disorders
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
ZA201900869B (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
ZA201901055B (en) Treatment and prevention of sleep disorders
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
ZA201904966B (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
ZA201704726B (en) Peptides and their use in the treatment of skin
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
ZA201904967B (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
GB2561132B (en) Systems and methods of assisting in the delivery of products
HUE067036T2 (hu) 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
GB201514018D0 (en) Novel tricyclic compounds and their use in the treatment of cancer
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections
IL261240B (en) Preparations useful in the prevention and/or treatment of inflammation and pain
HK40020424A (en) Sulfinylpyridines and their use in the treatment of cancer
HK40013929A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
HK40021223A (en) Bicyclic compounds and their use in the treatment of cancer
AU2016905362A0 (en) Compounds and use thereof in methods of treatment